Premium
Extemporaneous Isoniazid Mixture: Stability Implications
Author(s) -
Haywood Alison,
Mangan Martina,
Grant Gary,
Glass Beverley
Publication year - 2005
Publication title -
journal of pharmacy practice and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.222
H-Index - 22
eISSN - 2055-2335
pISSN - 1445-937X
DOI - 10.1002/j.2055-2335.2005.tb00333.x
Subject(s) - isoniazid , lactose , medicine , excipient , dose , differential scanning calorimetry , chromatography , pharmacology , tuberculosis , food science , chemistry , pathology , physics , thermodynamics
Background Isoniazid mixtures are compounded in Australia using commercially available isoniazid tablets. Aim To determine the stability of isoniazid 10 mg/mL mixture compounded from commercially available isoniazid tablets. Method The stability of the compounded isoniazid mixture stored at a range of temperatures (4–60 °C) was assessed with high performance liquid chromatography. Differential scanning calorimetry was used to investigate the compatibility of isoniazid with the excipient, lactose. Results The compounded isoniazid mixture exhibited significant degradation (≥ 10% after 3 days at 4 and 25 °C), whereas the control (using isoniazid powder) retained desired stability (> 90% at 30 days) under identical conditions. A replicate control formulation, spiked with lactose, produced statistically similar degradation profiles to that of the compounded isoniazid mixture (p > 0.05), indicating lactose to be responsible for the degradation of isoniazid. The thermoanalytical studies demonstrated an incompatibility between isoniazid and lactose (broadening and shifting of melting endotherm of isoniazid at 171.46 °C). Conclusion The British Pharmaceutical Codex specifies the use of isoniazid powder for compounding isoniazid mixture. This study highlights the importance for stability evaluations on all modified extemporaneous preparations in order to ensure that quality pharmaceuticals are delivered to patients.